The extent of individuals’ mobility within their community-;how much they get out and about-;may be linked to their cognitive function, according to new research published in the Journal of the American Geriatrics Society.
Gilead’s newest acquisition: a liver disease drug with $1B in peak sales potential
Gilead’s acquisition of CymaBay Therapeutics underscores the company’s historic success in liver diseases and could bring in $1 billion in peak annual sales. Gilead announced